The data safety monitoring board (DSMB) observed a continued acceptable safety profile, and evidence of a consistent pharmacological effect of its Phase II drug, VIA-2291.
Dr Adeoye Olukotun, chief medical officer, said: “VIA intends to continue the current Phase II trials, and to initiate additional clinical studies. VIA is very encouraged that the safety profile of VIA-2291 indicates that it is well tolerated in patients, and that evidence of a positive pharmacological effect has been observed by the DSMB. We believe that a drug that addresses vascular inflammation in the treatment of atherosclerosis will address a significant unmet medical need.”
VIA expects the top line results from the two Phase II trials for acute coronary syndrome and carotid endarterectomy patients in the middle of 2008.